Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Moxifloxacin vs amoxicillin‐clavulanate

SAEs · NSTI

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.63 [0.3, 1.31]
1 study · 54 participants
Very low

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
RR 0.97 [0.74, 1.27]
4 studies · 3548 participants
Moderate